Abstract
The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodinerefractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.
Keywords: thyroid stimulating hormone, RET/PTC oncogene, TP53 Tumor Suppressor Gene, Chemotherapy, vascular endothelial growth factor (VEGF)
Reviews on Recent Clinical Trials
Title: Iodine-Refractory Thyroid Carcinoma
Volume: 1 Issue: 2
Author(s): Apar K. Ganti and Ezra E.W. Cohen
Affiliation:
Keywords: thyroid stimulating hormone, RET/PTC oncogene, TP53 Tumor Suppressor Gene, Chemotherapy, vascular endothelial growth factor (VEGF)
Abstract: The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodinerefractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.
Export Options
About this article
Cite this article as:
Ganti K. Apar and Cohen E.W. Ezra, Iodine-Refractory Thyroid Carcinoma, Reviews on Recent Clinical Trials 2006; 1 (2) . https://dx.doi.org/10.2174/157488706776876526
DOI https://dx.doi.org/10.2174/157488706776876526 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Animal Models of Xenobiotic Receptors
Current Drug Metabolism Characterization of Hypersecreting or Non-Hypersecreting Adrenal Adenomas: Comparison between Iodine-131 Nor-Cholesterol Scintigraphy and Magnetic Resonance Imaging
Current Radiopharmaceuticals Apolipoprotein E Knockout Models
Current Pharmaceutical Design Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Effects of <i>Nigella Sativa</i> (Black seeds) Supplementation on Plasma Lipid Profile in Human Subjects - A Review
Current Nutraceuticals Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Ontogeny of Hepatic Glucuronidation; Methods and Results
Current Drug Metabolism Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Osteoblast Differentiation and Control by Vitamin D and Vitamin D Metabolites
Current Pharmaceutical Design Nephrotoxicity of Bisphenol A (BPA) -An Updated Review
Current Molecular Pharmacology The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Gene Profile Identifies Zinc Transporters Differentially Expressed in Normal Human Organs and Human Pancreatic Cancer
Current Molecular Medicine Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Research Progress in Natural Bioactive Constituents against Lipid Metabolic Diseases
Current Topics in Medicinal Chemistry Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Medical Treatment of Hirsutism in Women
Current Medicinal Chemistry Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism